THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Quint Company has been a cornerstone of the pharmaceutical industry for more than a century, building a legacy of quality and exceptional customer service. The long-enduring enterprise is a leading provider of print mats for the pharmaceutical and nutraceutical industries, offering an extensive array of materials that exceed client expectations. Quint’s commitment to uncompromising quality has remained steadfast through generations. Every flexographic printing plate is meticulously verified through a proprietary 200-point checklist, an industry gold standard, to ensure regulatory compliance and flawless performance. “We are built on a foundation of quality, which remains the core of everything we do,” says Eric Sandberg, owner. Shaping the Future of Print Innovation Deep industry expertise evolved over innovation that began in 1849, when S.H. Quint founded the company in the heart of Philadelphia. He started by creating stencils, stamps and marking supplies that left indelible impressions on crates and barrels destined for global markets. As printing technology evolved, Quint emerged as a full-service manufacturer, delivering state-of-the-art printing plates. Over time, it advanced from vulcanized rubber to photopolymer plates, continually reinventing its product line. In the mid-20th century, leadership transitioned from the Quint family to the Davis family, which brought renewed focus on adapting to dynamic market demands. In the 1980s, under the visionary guidance of Richard Davis Jr, Quint pioneered pharmaceutical printing with innovations in barcode and blister packaging. Davis’ deep commitment to regulatory excellence and collaboration with organizations like the UCC and FDA took precision and efficiency a notch higher. Quint continues its tradition of quality craftsmanship, producing historic plaques for the City of Philadelphia, USDA-approved meat inspection stamps, and custom printing stamps. Excellence in Every Print, Impact in Every Delivery Quality is the pulse of Quint. It has perfected FDA-compliant barcoding solutions in an industry where precision is paramount. Plates are engineered for exceptional accuracy, with the team ensuring efficient operations and quick turnaround times. Orders placed by 11AM are transformed into carefully crafted plates and shipped out the same day, highlighting its steadfast dedication and operational excellence.
Managing controlled substances demands expert oversight. GTC Consulting stands apart in the DEA compliance space by leading with a proactive, results-oriented approach. Rather than reacting to violations or audits, GTC anticipates regulatory changes, identifies compliance gaps early and implements forward-thinking solutions. This strategy protects clients from enforcement actions, costly fines, and reputational damage. GTC provides specialized regulatory guidance to pharmaceutical manufacturers, distributors and healthcare entities at the federal and state levels. It serves a diverse client base, from small businesses to Fortune 500 companies, helping them maintain compliance by assisting with DEA registrations and state licenses. It also conducts regulatory audits to identify compliance gaps and help clients stay ahead of evolving requirements. What truly differentiates GTC is its comfort with complexity. The team embraces high-risk and nontraditional challenges that fall outside the typical scope of DEA consulting, bringing deep regulatory expertise and strategic agility to every engagement. “Our battle-tested experience goes a long way in helping clients truly understand the totality of the risks,” says Benjamin F. Mink, president and CEO. A team of seasoned experts, including Ph. D.-level doctors and former DEA leadership, brings deep industry knowledge and strategic insight. It helps clients meet compliance standards and develop proactive strategies to protect their operations. In today’s high-risk regulatory environment, companies can’t afford guesswork. GTC delivers insight shaped by real regulatory battles and legal proceedings—giving leaders the clarity and confidence to move forward. It’s experts have testified before the U.S. Congress and worked on criminal trials involving executives prosecuted for pharmaceutical distribution violations. This expertise equips it to serve clients with practical, real-world insights to better understand their obligations and effectively mitigate risk.
eClinical Trial Management
Haichen Yang, MD, MA, MBA, Vice President, Clinical Research, Amicus Therapeutics Inc [NASDAQ: FOLD]
Pharma Manufacturing
Alexis Bossie, Head of Media R&D, Lonza
Pharma Manufacturing
Armand Matejunas, Sr. Director, Clinical Data Operations, Pacira BioSciences, Inc
Drug Discovery and Development
Jeffrey W. Sherman, Chief Medical Officer Emeritus, Horizon Therapeutics Now Amgen
Pharma Manufacturing
Tom Janiszewski, Labeling Project Manager II, AbbVie
Drug Discovery Enabling
Hua Gong, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab (US) LLC
Pharma Consulting
Jennifer Perrin, Director, MMS Holdings Inc
Pharmaceutical flexographic printing plates have become essential in the packaging and labeling processes of the pharmaceutical sector.
Shaping the Future of Pharma Risk
On the distribution side, traditional compliance models can no longer keep pace with rising regulatory scrutiny. Companies now use AI-powered predictive analytics to detect real-time anomalies, flagging supply chain risks before they escalate. Blockchain adds another layer of control, embedding transparency and traceability across the chain to prevent counterfeiting and unauthorized distribution.
These tools have become operational necessities. With tighter global rules, pharmaceutical firms invest in real-time monitoring systems that detect diversion risks and enforce chain-of-custody controls. The aim is to reduce risk while gaining a competitive edge through precision and preparedness.
Packaging is evolving in parallel. As sustainability goals and labelling requirements grow more demanding, the flexographic printing industry is adapting fast. Digital flexo plates offer higher print quality and less waste, supporting eco-conscious packaging initiatives without compromising performance. Hybrid press technology speeds up production and enables greater flexibility, making it easier to keep up with evolving compliance standards.
As a result, the Controlled Substance Distribution Risk Management market is projected to grow at a CAGR of 6.6 percent through 2025, while the Pharmaceutical Flexographic Printing Plates industry is expected to grow at 6.69 percent annually through 2033.
The magazine features a thought leadership piece by Haichen Yang, MD, MA, MBA, Vice President of Clinical Research at Amicus Therapeutics, discussing the challenges of placebo-controlled trials in gene therapy and the FDA’s growing acceptance of historical data as alternative controls. It also includes insights from Jennifer Perrin, Associate Director of Quality & Compliance at MMS Holdings, on the benefits and risks of outsourcing quality functions in pharma, highlighting the need for qualified consultants and strict regulatory adherence.
We also spotlight the stories of pharmaceutical companies delivering solutions that drive innovation. One such company is Quint Company, which has developed precision-engineered flexographic plates, FDA-compliant barcoding and rigorous quality control.
In this edition featuring the Best Pharmaceutical Security & DEA Compliance Consulting Firm 2025 and Top Pharmaceutical Flexographic Printing Plates Supplier 2025, we hope you find the right partner to meet your organization’s needs.
